ABOS News and Press, Acumen Pharmaceuticals Inc. From 04/16/24

Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changes Presentation to be featured during AAN Emerging Science Session Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 ...

2024-04-04 09:01:25 ET More on Acumen Pharmaceuticals Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Call Transcript Acumen Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Acumen Pharmaceuticals ...

Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approved Sabirnetug is the first monoclonal antibody candidate to enter the clinic developed to selectively target toxic soluble amyloid beta oligomers, which evid...

2024-03-27 16:58:40 ET More on Acumen Pharmaceuticals Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Call Transcript Acumen Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Acumen Pharmaceuticals ...

2024-03-26 10:45:17 ET Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Conference Call March 26, 2024 08:00 A.M. ET Company Participants Alex Braun - Head, IR Daniel O'Connell - CEO Eric Siemers - Chief Medical Officer Matthew Zuga - CFO & Chief Busi...

2024-03-26 07:03:57 ET More on Acumen Pharmaceuticals Seeking Alpha’s Quant Rating on Acumen Pharmaceuticals Historical earnings data for Acumen Pharmaceuticals Financial information for Acumen Pharmaceuticals Read the full article on Seeking Alpha ...

Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...

Initiation of a Phase 2 study, ALTITUDE-AD, to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease expected in the first half of 2024 Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024 Cash, ...

- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets sol...

CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the tre...